Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

Elizabeth Plimack, MD
Published: Friday, Jul 15, 2016

 
Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses the role of nivolumab in kidney cancer.
 
We now have long-term follow-up data from patients that have been on nivolumab for four to five years, says Plimack. About one-third of patients are still alive at four years.
 
This long-term benefit occurred in patients regardless of their initial response to therapy and risk group.
 
Biomarker development is needed, and as well as research regarding adverse events and combination possibilities. A lot can still be learned regarding how nivolumab should be used in kidney cancer, says Plimack.
 
 
Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses the role of nivolumab in kidney cancer.
 
We now have long-term follow-up data from patients that have been on nivolumab for four to five years, says Plimack. About one-third of patients are still alive at four years.
 
This long-term benefit occurred in patients regardless of their initial response to therapy and risk group.
 
Biomarker development is needed, and as well as research regarding adverse events and combination possibilities. A lot can still be learned regarding how nivolumab should be used in kidney cancer, says Plimack.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x